查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1726078

分子影像的全球市场，市场规模和占有率的分析 - 成长趋势与预测(2025年～2033年)

Molecular Imaging Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

分子影像市场趋势及总结

预计2033年，全球分子影像市场规模将从2024年的79.6亿美元增至123.6亿美元，2025年至2033年的复合年增长率为5.01%。这得益于疾病早期诊断需求的不断增长、影像诊断技术的创新以及癌症和神经系统疾病盛行率的不断上升，而分子影像在精准诊断和个人化治疗中发挥关键作用。

分子影像市场成长的推动因素

慢性病盛行率的不断上升

癌症、心血管疾病和神经系统疾病等慢性病盛行率的不断上升是分子影像产业发展的主要推动因素。此类疾病需要早期准确诊断，而分子成像透过在分子和细胞层面上可视化生物功能，实现了早期准确诊断。这些技术可以改善疾病的检测、分期和监测，从而改善患者的预后，并增加对下一代影像技术的需求。每年有1800万人死于心血管疾病，这些疾病会影响心臟和血管，导致心臟病发作、中风和心臟衰竭。每年约有900万人死于癌症，400万人死于气喘和慢性阻塞性肺病等慢性呼吸道疾病，200万人死于糖尿病。然而，疾病负担和现代医疗保健的可近性分布不均。

影像诊断的进步

随着PET/CT和PET/MRI等混合影像模式的引入，影像诊断技术的不断进步改变了诊断的可能性。这些进步使得影像解析度更高、灵敏度更高，并有可能在早期发现疾病。这些技术进步不仅提高了诊断的准确性，还增加了分子影像在个人化医疗中的应用，从而推动了市场成长。 2024年6月，Lantheus Holdings, Inc. 宣布收购了Life Molecular Imaging公司针对胃泌素释放肽受体(GRPR)的RM2药物的全球权利。这些权利包括临床阶段的放射治疗药物177Lu-DOTA-RM2和放射诊断药物68Ga-DOTA-RM2。此次收购将拓宽Lantheus的研发管线，使其涵盖乳癌和其他癌症，并专注于摄护腺癌。该交易包括3500万美元的预付款，以及潜在的里程碑付款和特许权使用费。

研发创新

目前，公司正在投入大量资金进行研发，以寻找新的造影剂并增强现有的影像模式。这对于分子影像技术的进步至关重要，因为它有助于开发更有效率的诊断和治疗方法。专注于研发将支持市场成长，并带来一系列新的解决方案来填补临床需求的空缺。据美国放射学会称，总统2024财年预算大幅增加了对美国国家癌症研究所 (NCI) 的可自由支配资金，达到7.16亿美元，比2023财年的拨款增加了5亿美元。这笔资金将用于推进研究、预防、诊断和治疗工作，这些工作都高度依赖放射学和影像技术。

分子影像市场面临的课题

影像设备和程式成本高

先进分子影像设备和程序的高成本是市场扩张的主要障碍。高昂的购买和维护成本限制了这些技术的使用，尤其是在发展中国家和小型医疗中心。造影剂的成本和对技术人员的需求也推高了营运成本，阻碍了技术的广泛应用。

监理与报销课题

在复杂的监管环境中游刃有余并获得分子影像程式的报销仍然具有课题性。严格的监管环境可能会阻碍新型成像剂和设备的批准和商业化。此外，不同地区不同的报销政策也会影响分子影像服务的可近性和成本，进而影响市场渗透率。

本报告提供全球分子影像市场相关调查，成长推动因素与课题，各市场区隔的分析，主要企业的分析等资讯。

目录

第1章 简介

第2章 调查手法

第3章 摘要整理

第4章 市场动态

  • 成长促进因素
  • 课题

第5章 分子影像市场

  • 过去的市场趋势
  • 市场预测

第6章 分子影像的市场占有率分析

  • 各种模式
  • 各用途
  • 各最终用途
  • 各国

第7章 模式

  • 单一光子辐射断层摄影(SPECT)
  • 正子辐射断层摄影(PET)
  • 核磁共振光谱仪
  • 分子超音波成像
  • 其他

第8章 用途

  • 肿瘤
  • 心血管
  • 神经
  • 呼吸系统
  • 消化器官

第9章 最终用途

  • 医院
  • 影像诊断中心
  • 研究机关

第10章 国家

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 比利时
    • 荷兰
    • 土耳其
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 泰国
    • 马来西亚
    • 印尼
    • 澳洲
    • 纽西兰
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东·非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 南非

第11章 波特的五力分析

第12章 SWOT分析

第13章 主要企业的分析

  • GE HealthCare
  • Siemens Healthineers AG
  • Koninklijke Philips N.V.
  • Shimadzu Corp
  • United Imaging Healthcare Co., Ltd.
  • Bruker Corp
  • FUJIFILM Holdings Corp
  • Cubresa Inc.
简介目录

Molecular Imaging Market Trends & Summary

The Molecular Imaging Market is anticipated to grow to US$ 12.36 billion by 2033 from US$ 7.96 billion in 2024, at a CAGR of 5.01% during the period from 2025 to 2033. This is fueled by increasing demand for early disease diagnosis, technological innovations in imaging modalities, and rising incidence of cancer and neurological diseases, where molecular imaging plays a critical role in precision diagnosis and personalized treatment.

The report Molecular Imaging Market & Forecast covers by Modality (Single Photon Emission Computed Tomography, Psitron Emmission Tomography, Nuclear Magnetic Resonance Spectrometer, Molecular Ultrasound Imaging, Others), Application (Oncology, Cardiovascular, Neurology, Respiratory, Gastrointestinal), End Use (Hospitals, Diagnostic Imaging Centers, Research Institutes), Country and Company 2025-2033.

Molecular Imaging Market Outlooks

Molecular imaging is a cutting-edge biomedical technology that facilitates visualization, characterization, and measurement of biological functions at the molecular and cellular level within living systems. In contrast to conventional imaging technologies that merely concentrate on anatomical structures, molecular imaging yields extensive information regarding how tissues and organs work in real-time. It integrates imaging modalities like positron emission tomography (PET), single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), and optical imaging with molecular probes or biomarkers.

Molecular imaging is essential in the early disease detection and follow-up of conditions like cancer, cardiovascular disease, and neurological diseases like Alzheimer's and Parkinson's disease. It assists in assessing the effectiveness of a treatment by monitoring biological reactions at the molecular level. It also assists in drug discovery since researchers can monitor how new drugs interact with biological targets in living organisms. Its non-invasive character and capability to deliver accurate, functional information make molecular imaging a pillar of personalized medicine.

Growth Drivers in the Molecular Imaging Market

Increased Incidence of Chronic Diseases

The growing prevalence of chronic diseases like cancer, cardiovascular disease, and neurological conditions is a key growth driver for the molecular imaging industry. Such diseases require early and precise diagnosis, which molecular imaging makes possible through the visualization of biological functions at the molecular and cellular levels. Such a capability improves the detection, staging, and monitoring of disease, improving patient outcomes and driving demand for next-generation imaging technology. Every year 18 million individuals succumb to cardiovascular diseases that involve the heart and blood vessels and can result in heart attacks, stroke, or heart failure. Approximately 9 million individuals die annually from cancers, 4 million from chronic respiratory diseases like asthma or COPD, and 2 million from diabetes. But both disease burden and access to contemporary health care are disproportionately allocated.

Advances in Imaging Modalities

Ongoing advances in imaging modalities, with the introduction of hybrid imaging modalities such as PET/CT and PET/MRI, have transformed diagnostic potential. These advances provide images with greater resolution, increased sensitivity, and the potential to detect illnesses at earlier stages. These technological advances not only improve diagnostic precision but also increase the utilization of molecular imaging in personalized medicine, thus boosting market growth. June 2024, Lantheus Holdings, Inc. reported its acquisition of worldwide rights to Life Molecular Imaging's RM2, targeting the gastrin-releasing peptide receptor (GRPR). These include the clinical-stage radiotherapeutic 177Lu-DOTA-RM2 and the radiodiagnostic 68Ga-DOTA-RM2. The acquisition strengthens Lantheus' emphasis on prostate cancer and broadens its pipeline to breast and other cancers, with an upfront payment of $35 million plus possible milestone payments and royalties.

Innovation in Research and Development

Higher expenditure in research and development processes to identify new imaging agents and enhance current imaging methods is underway. It is vital for the development of molecular imaging, as it results in the creation of more efficient diagnostic methods and treatments. The focus on R&D provides a stream of new solutions, which supports growth in the market and fills gaps in clinical need. As per the America College of Radiology, The president's 2024 budget included a substantial increase in discretionary funding for the National Cancer Institute (NCI) to USD 716 million, a USD 500 million increase from the FY 2023 allocation. The funds are to be used to advance research, prevention, diagnosis, and treatment efforts, all of which rely extensively on radiology and imaging technology.

Challenges in the Molecular Imaging Market

High Cost of Imaging Equipment and Procedures

The high cost of advanced molecular imaging equipment and procedures is a major hindrance to market expansion. High acquisition and maintenance expenses restrict the use of these technologies, especially in developing countries and small healthcare centers. The cost of imaging agents and the requirement for skilled personnel also drive up operational costs, preventing widespread adoption.

Regulatory and Reimbursement Challenges

Working with the intricate regulatory environment and gaining reimbursement for molecular imaging procedures is still difficult. The strict regulatory environment can hold up the approval and commercialization of new imaging agents and devices. In addition, variable reimbursement policies between different regions can impact the availability and cost of molecular imaging services, which can influence market penetration.

Molecular Ultrasound Imaging Market

Molecular ultrasound imaging integrates conventional ultrasound methods with targeted contrast agents to image particular molecular markers in the body. Molecular ultrasound imaging is a non-invasive technique with real-time imaging and high spatial resolution, and it is worth its weight in gold for early disease detection and monitoring therapeutic interventions. Its low cost of entry and favorable safety profile over other imaging modalities make it increasingly popular in the clinical environment.

Oncology Molecular Imaging Market

In cancer, molecular imaging is a central component of early detection, staging, and monitoring of cancer. Modalities such as PET and SPECT allow visualization of tumor metabolism and receptor expression and thus insight into tumor biology. Such information is invaluable for choosing the right therapies, evaluating treatment response, and detecting recurrences, thus enhancing patient management and outcomes.

Neurology Molecular Imaging Market

Molecular imaging plays a crucial role in diagnosing and managing neurological disorders such as Alzheimer's disease, Parkinson's disease, and epilepsy. By visualizing distinct neurotransmitter systems and pathological protein accumulations, these imaging techniques enable early diagnosis and monitoring of disease progression. This ability fosters a greater understanding of neurological disease and aids in the creation of targeted therapeutics.

Respiratory Molecular Imaging Market

Molecular imaging is supporting the evaluation of diseases such as chronic obstructive pulmonary disease (COPD), asthma, and lung cancer in respiratory medicine. Molecular imaging helps in imaging inflammatory processes, ventilation-perfusion mismatches, and tumor metabolism. All of this information guides clinicians to tailor treatment regimens, follow the therapeutic responses, and enhance the outcomes of the patients.

Molecular Imaging Hospitals Market

Hospitals are the first adopters of molecular imaging technologies because of their complete diagnostic and therapeutic facilities. Incorporation of molecular imaging in hospitals improves diagnostic accuracy, informs treatment planning, and enables personalized medicine strategies. Multidisciplinary teams and advanced infrastructure available in hospitals enable effective use of these imaging modalities.

Molecular Imaging in Research Institutes

Research institutes utilize molecular imaging to study mechanisms of disease, assess emerging treatments, and generate new imaging probes. The institutes are significant players in expanding the field by engaging in preclinical and clinical investigations that directly guide clinical care. Research institutes working together with industry partners are at the heart of driving innovation and shaping advances in molecular imaging technology.

United States Molecular Imaging Market

The United States is a large market for molecular imaging, with high incidence of chronic diseases, sophisticated healthcare infrastructure, and high research and development investment. The availability of top imaging technology firms and academic institutions encourages innovation and uptake of advanced imaging modalities. Favorable regulatory environments and reimbursement policies also encourage market growth. November 2024, United Imaging installed the world's first uMI Panvivo PET/CT at Pueblo Medical Imaging in Nevada, USA. The next-generation platform boasts a best-in-class NEMA spatial resolution of 2.9 mm* and an effective sensitivity of 181 cps/kBq. Equipped with its AI-based 3D camera technology, the uMI Panvivo brings precision and care to all.

Germany Molecular Imaging Market

Germany's molecular imaging market is marked by strong healthcare infrastructure, high focus on medical research, and positive reimbursement policies. The precision medicine and early disease detection focus of the country facilitates the uptake of advanced imaging technologies. Academic-industry collaborations help in the development and deployment of innovative imaging solutions. United Imaging has deployed its innovative molecular imaging technology in Germany, partnering with Medical Imaging Electronics (MiE). The Kliniken Essen-Mitte Evang and Nukmed are now equipped with the uMI 550 digital PET/CT system, a cutting-edge system.

India Molecular Imaging Market

The molecular imaging market in India is growing, supported by growing healthcare consciousness, rising chronic disease incidence, and increasing investments in healthcare infrastructure. Government policies promoting diagnostic ability and access to advanced medical technologies are driving market expansion. The emergence of affordable imaging solutions optimized for the Indian populace is also driving market growth. May 2025, Mahajan Imaging & Labs has inaugurated North India's first 128-Slice Digital PET-CT - Omni Legend by GE HealthCare, along with a state-of-the-art pathology lab in Gurugram. This new center is a major step forward in integrated cancer care and diagnostics for Delhi NCR.

Saudi Arabia Molecular Imaging Market

Saudi Arabia is experiencing growth in the molecular imaging market because of the increasing burden of chronic diseases, government investment in healthcare modernization, and initiatives to improve diagnostic capabilities. The Vision 2030 initiative of the country focuses on the development of sophisticated healthcare services, including the implementation of cutting-edge imaging technologies. Partnerships with global players and investments in health infrastructure facilitate the growth of the market. December 2024, King Abdulaziz University (KAU) has initiated a groundbreaking Alzheimer's disease diagnosis service at its Molecular Imaging Center (I-One) via Wadi Jeddah. This service is provided using combined Positron Emission Tomography and Magnetic Resonance Imaging (PET/MRI), making it the first of its nature in Saudi Arabia.

Molecular Imaging Market Segmentation

Modality

  • Single Photon Emission Computed Tomography
  • Psitron Emmission Tomography
  • Nuclear Magnetic Resonance Spectrometer
  • Molecular Utrasound Imaging
  • Others

Application

  • Oncology
  • Cardiovascular
  • Neurology
  • Respiratory
  • Gastrointestinal

End Use

  • Hospitals
  • Diagnostic Imaging Centers
  • Research Institutes

Countries

North America

  • United States
  • Canada

Europe

  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Belgium
  • Netherlands
  • Turkey

Asia Pacific

  • China
  • Japan
  • India
  • South Korea
  • Thailand
  • Malaysia
  • Indonesia
  • Australia
  • New Zealand

Latin America

  • Brazil
  • Mexico
  • Argentina

Middle East & Africa

  • Saudi Arabia
  • UAE
  • South Africa

All companies have been covered with 4 Viewpoints

  • Overview
  • Key Persons
  • Recent Development & Strategies
  • Revenue Analysis

Key Players Analysis

  • GE HealthCare
  • Siemens Healthineers AG
  • Koninklijke Philips N.V.
  • Shimadzu Corp
  • United Imaging Healthcare Co., Ltd.
  • Bruker Corp
  • FUJIFILM Holdings Corp
  • Cubresa Inc.

Table of Contents

1. Introduction

2. Research Methodology

  • 2.1 Data Source
    • 2.1.1 Primary Sources
    • 2.1.2 Secondary Sources
  • 2.2 Research Approach
    • 2.2.1 Top-Down Approach
    • 2.2.2 Bottom-Up Approach
  • 2.3 Forecast Projection Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Molecular Imaging Market

  • 5.1 Historical Market Trends
  • 5.2 Market Forecast

6. Molecular Imaging Market Share Analysis

  • 6.1 By Modality
  • 6.2 By Application
  • 6.3 By End Use
  • 6.4 By Countries

7. Modality

  • 7.1 Single Photon Emission Computed Tomography
  • 7.2 Psitron Emmission Tomography
  • 7.3 Nuclear Magnetic Resonance Spectrometer
  • 7.4 Molecular Utrasound Imaging
  • 7.5 Others

8. Application

  • 8.1 Oncology
  • 8.2 Cardiovascular
  • 8.3 Neurology
  • 8.4 Respiratory
  • 8.5 Gastrointestinal

9. End Use

  • 9.1 Hospitals
  • 9.2 Diagnostic Imaging Centers
  • 9.3 Research Institutes

10. Countries

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
  • 10.2 Europe
    • 10.2.1 France
    • 10.2.2 Germany
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Belgium
    • 10.2.7 Netherlands
    • 10.2.8 Turkey
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Thailand
    • 10.3.6 Malaysia
    • 10.3.7 Indonesia
    • 10.3.8 Australia
    • 10.3.9 New Zealand
  • 10.4 Latin America
    • 10.4.1 Brazil
    • 10.4.2 Mexico
    • 10.4.3 Argentina
  • 10.5 Middle East & Africa
    • 10.5.1 Saudi Arabia
    • 10.5.2 UAE
    • 10.5.3 South Africa

11. Porter's Five Forces Analysis

  • 11.1 Bargaining Power of Buyers
  • 11.2 Bargaining Power of Suppliers
  • 11.3 Degree of Rivalry
  • 11.4 Threat of New Entrants
  • 11.5 Threat of Substitutes

12. SWOT Analysis

  • 12.1 Strength
  • 12.2 Weakness
  • 12.3 Opportunity
  • 12.4 Threat

13. Key Players Analysis

  • 13.1 GE HealthCare
    • 13.1.1 Overview
    • 13.1.2 Key Persons
    • 13.1.3 Recent Development & Strategies
    • 13.1.4 Revenue Analysis
  • 13.2 Siemens Healthineers AG
    • 13.2.1 Overview
    • 13.2.2 Key Persons
    • 13.2.3 Recent Development & Strategies
    • 13.2.4 Revenue Analysis
  • 13.3 Koninklijke Philips N.V.
    • 13.3.1 Overview
    • 13.3.2 Key Persons
    • 13.3.3 Recent Development & Strategies
    • 13.3.4 Revenue Analysis
  • 13.4 Shimadzu Corp
    • 13.4.1 Overview
    • 13.4.2 Key Persons
    • 13.4.3 Recent Development & Strategies
    • 13.4.4 Revenue Analysis
  • 13.5 United Imaging Healthcare Co., Ltd.
    • 13.5.1 Overview
    • 13.5.2 Key Persons
    • 13.5.3 Recent Development & Strategies
    • 13.5.4 Revenue Analysis
  • 13.6 Bruker Corp
    • 13.6.1 Overview
    • 13.6.2 Key Persons
    • 13.6.3 Recent Development & Strategies
    • 13.6.4 Revenue Analysis
  • 13.7 FUJIFILM Holdings Corp
    • 13.7.1 Overview
    • 13.7.2 Key Persons
    • 13.7.3 Recent Development & Strategies
    • 13.7.4 Revenue Analysis
  • 13.8 Cubresa Inc.
    • 13.8.1 Overview
    • 13.8.2 Key Persons
    • 13.8.3 Recent Development & Strategies